Date:1/30/2013

/sup> outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), and Pleth Variability Index (PVI^®), in addition to SpO₂, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow^® Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow^® SET^® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine^®, a pioneer in the development of innovative brain function monitoring technology and devices. And in 2012, Masimo acquired the assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET^® and Masimo rainbow^® SET^® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving
'/>"/>

SOURCE Masimo Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Masimo Showcases Advanced, Noninvasive Patient Monitoring Technologies at Arab Health
2. Masimo Reports Third Quarter 2012 Financial Results; Board Declares Special Cash Dividend of $1.00 per Share
3. Masimo to Present at Lazard Capital Markets 9th Annual Healthcare Conference
4. Kennedy Health System Renews System-Wide Pulse Oximetry Contract with Masimo
5. Masimo Reschedules Release of Third Quarter 2012 Financial Results and Associated Conference Call to Thursday, November 1st Due to Hurricane Sandy
6. Inova Health System Re-Ups System-wide Pulse Oximetry Contract with Masimo
7. Masimo to Host Investor Day on September 20
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Masimo Corporation in Connection with Executive Compensation
9. Masimos Noninvasive Pleth Variability Index as Accurate as Invasive Stroke Volume Variation for Fluid Responsiveness Assessment in Cardiac Surgery
10. Masimo Enters Noninvasive Multigas Monitoring, including Capnography, with Acquisition of PHASEIN
11. Masimo Reports Second Quarter 2012 Financial Results